Expert Analysis

Lymphomas

Source: CCO Independent Conference Coverage of the American Society of Hematology 2008 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Lymphomas

CME Program Director: Roy A. Beveridge, MD

Faculty:

Steven H. Bernstein, MD
Owen A. O'Connor, MD, PhD
Julie M. Vose, MD

Peter J. Rosen, MD

CREDIT INFORMATION

Release Date: February 20, 2009

Expiration Date: February 19, 2010

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data on the use of novel agents in mantle cell lymphoma
Describe how minimal residual disease affects outcome in mantle cell lymphoma
Discuss recent advances in the treatment of T-cell lymphomas
Explain novel approaches to passive and active immunotherapy in non-Hodgkin’s lymphoma

Topics covered include:

Bortezomib Plus Rituximab-Modified HyperCVAD in Treatment-Naive Patients With Mantle Cell Lymphoma
Achieving Molecular Remission as Prognostic Factor in Patients With Mantle Cell Lymphoma
Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma: Results of Phase II NHL-003 Trial
Clinical Research Considerations for Mantle Cell Lymphoma
Pralatrexate Active in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results of PROPEL Study
HDAC Inhibitor Romidepsin for Advanced-Stage, Refractory Cutaneous T-Cell Lymphoma
Syk Inhibitor Fostamatinib in Relapsed/Refractory DLBCL and Chronic Lymphocytic Leukemia
Patient-Specific Immunotherapy With Mitumprotimut-T After Rituximab in Follicular Lymphoma
Low Dose of T-Cell–Stimulating Antibody Blinatumomab in Relapsed Non-Hodgkin’s Lymphoma
Combination of Inotuzumab and Rituximab in Relapsed Follicular Lymphoma and DLBCL Patients
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.